| Literature DB >> 32990748 |
Chun-Jie Liu1,2, Xin Fu2, Mengxuan Xia2, Qiong Zhang2, Zhifeng Gu1,3, An-Yuan Guo1,2.
Abstract
MicroRNAs (miRNAs) related single-nucleotide variations (SNVs), including single-nucleotide polymorphisms (SNPs) and disease-related variations (DRVs) in miRNAs and miRNA-target binding sites, can affect miRNA functions and/or biogenesis, thus to impact on phenotypes. miRNASNP is a widely used database for miRNA-related SNPs and their effects. Here, we updated it to miRNASNP-v3 (http://bioinfo.life.hust.edu.cn/miRNASNP/) with tremendous number of SNVs and new features, especially the DRVs data. We analyzed the effects of 7 161 741 SNPs and 505 417 DRVs on 1897 pre-miRNAs (2630 mature miRNAs) and 3'UTRs of 18 152 genes. miRNASNP-v3 provides a one-stop resource for miRNA-related SNVs research with the following functions: (i) explore associations between miRNA-related SNPs/DRVs and diseases; (ii) browse the effects of SNPs/DRVs on miRNA-target binding; (iii) functional enrichment analysis of miRNA target gain/loss caused by SNPs/DRVs; (iv) investigate correlations between drug sensitivity and miRNA expression; (v) inquire expression profiles of miRNAs and their targets in cancers; (vi) browse the effects of SNPs/DRVs on pre-miRNA secondary structure changes; and (vii) predict the effects of user-defined variations on miRNA-target binding or pre-miRNA secondary structure. miRNASNP-v3 is a valuable and long-term supported resource in functional variation screening and miRNA function studies.Entities:
Year: 2021 PMID: 32990748 PMCID: PMC7778889 DOI: 10.1093/nar/gkaa783
Source DB: PubMed Journal: Nucleic Acids Res ISSN: 0305-1048 Impact factor: 16.971
Figure 1.Overview of data and features in miRNASNP-v3. miRNASNP-v3 integrated human SNVs from dbSNP v151, GWAS Catalog, ClinVar and COSMIC v88. Huge amount of SNPs and DRVs were identified on miRNAs and gene 3′UTRs regions. miRNASNP-v3 provides seven main functional modules for users to explore the effects of miRNA-related SNVs.
Data summary and comparisons with other databases
| Data item (human) | miRNASNP-v3 | miRNASNP-v2 | PolymiRTS 3.0 | miRdSNP | SomamiR 2.0 | MSDD | dbMTS |
|---|---|---|---|---|---|---|---|
| Number of SNPs on miRNA seed regions | 6229 | 227 | 294 | N.A. | N.A. | N.A. | N.A. |
| Number of SNPs on pre-miRNAs | 46 826 | 2257 | N.A. | N.A. | N.A. | N.A. | N.A. |
| Number of SNPs on 3′UTRs | 7 115 796 | 566 176 | 427 096 | 175 351 | N.A. | N.A. | 5 318 919 |
| Number of DRVs on miRNA seed regions | 809 | N.A. | N.A. | N.A. | 181 | 5 | N.A. |
| Number of DRVs on pre-miRNAs | 4712 | N.A. | N.A. | N.A. | 1779 | 72 | N.A. |
| Number of DRVs on 3′UTRs | 265 697 | N.A. | N.A. | N.A. | 484 428 | 54 | 16 212 |
| Associated with GWAS SNPs | 235 085 | 131 686 | 4830 | 630 | N.A. | N.A. | 1571 |
| Experimental validated miRNA targets | 1 027 355 | 393 936 | 2070 | N.A. | 356 384 | N.A. | N.A. |
| Gain of targets by SNVs in miRNA seed regions | 14 491 855 | 162 441 | N.A. | N.A | N.A. | N.A. | N.A. |
| Loss of targets by SNVs in miRNA seed regions | 13 384 176 | 153 290 | N.A. | N.A | N.A. | N.A. | N.A. |
| Gain of targets by SNVs in 3′UTRs | 35 816 938 | 509 791 | 906 703 | 174 | N.A. | N.A. | N.A. |
| Loss of targets by SNVs in 3′UTRs | 37 427 973 | 445 737 | 923 082 | N.A. | N.A. | N.A. | N.A. |
| Number of mature miRNAs | 2652 | 2042 | 2578 | N.A. | 987 | 182 | 2588 |
| Secondary structure | Yes | Yes | No | No | No | No | No |
| Drug sensitivity | Yes | No | No | No | No | No | No |
| Diseases/Traits information | Yes | No | Yes | Yes | Yes | Yes | Yes |
| INDELs | Yes | Yes | Yes | No | No | No | No |
| miRNA/gene expression | Yes | Yes | No | No | No | No | Yes |
| Year of update | 2020 | 2015 | 2014 | 2012 | 2016 | 2017 | 2020 |
N.A. Not available.
The number of SNP in the table refers to SNPs and INDELs.
Figure 2.The utilities and new modules of miRNASNP-v3. (A) The SNVs in the seed regions and their effects on the target gains and losses. (B) The information of SNVs on gene 3′UTRs and their effects on the alteration of miRNA target binding. (C) The effects of SNVs on the changes of minimum free energy and secondary structure for pre-miRNAs. (D) The detail information of miRNA-target gain and loss, expression profiles, expression correlations and binding site details. (E) GO and KEGG pathway enrichment analysis for the gained or lost targets. (F) Correlations between drug sensitivity and the expression level of miRNAs. (G) Online prediction tools for potential alterations of miRNA target binding and secondary structure of a pre-miRNA for user customized sequences.